ModifiedCentenePolicy CPMP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Medical necessity criteria and coding guidance for facility-based polysomnography (PSG), split-night studies, and CPAP/BiPAP titration for suspected obstructive sleep apnea (OSA) in non‑Medicare Centene-affiliated health plans; includes when facility testing is required instead of home sleep apnea testing (HSAT).

Policy Summary

PayerCentene

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy CPMP.248

Change TypeAdded sections for repeat studies & titrationcoding updates

Effective Date

Next Review Date

Key ActionObtain prior authorization and document medical necessity when requesting facility-based PSG, split-night studies, or CPAP/BiPAP titration (CPT 95807, 95808, 95810, 95811) per the policy criteria.

SourceLink

POLICY UPDATE CHANGES

Expanded scope to include split-night studies and titration and changed references from 'sleep center' to 'facility-based' studies.

Added criteria indicating facility testing for mission-critical workers and BMI > 50.

Added sections II and III for repeat PSG/split-night studies and facility-based titration and added CPT code 95811.

Clarified that HSAT sensitivity is lower in low pretest probability of OSA and specified certain clinical details (e.g., chronic nocturnal oxygen use vs moderate-severe pulmonary impairment, NYHA references).

Removed Epworth Sleepiness Scale requirement and added specific symptom and hypertension language to criteria.

Added criteria sections II. and III. for repeat facility-based PSG/split-night studies and facility-based titration and added code 95811.

Revised criteria by removing requirement to meet criteria for facility-based sleep study and rewording failed APAP trial statement.

Corrected requirement to require either continuous nocturnal oxygen use OR moderate to severe pulmonary function impairment (instead of both).

Updated wording to include concerns for significant non-respiratory sleep disorders and added hypoventilation syndrome as an indication.

Removed Epworth Sleepiness Scale criteria and removed 'moderate-to-high-risk' verbiage in certain sections; added diagnosis of hypertension as a criterion in one subsection.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity and Coverage Criteria

Initial Therapy / Diagnostic PSG

Covered when ALL of the following are met

Age: Member/enrollee is >= 18 years of age>=18 years

Suspected OSA: Member/enrollee has suspected obstructive sleep apnea (OSA)

HSAT not appropriate: Portable/home apnea testing (HSAT) is not appropriate due to one or more of the following: HSAT services not available; member unable to operate or tolerate home equipment and no helper available; previous HSAT results negative or inadequate for diagnosis of suspected OSA; previous HSAT results negative or inadequate for autotitration of APAP for suspected OSA; chronic opioid use; low pretest probability of OSA (HSAT has lower sensitivity in this setting); BMI >= 50 kg/m2; member performs a mission-critical function (e.g., pilots, commercial drivers, security personnel); moderate to severe chronic pulmonary disease (documentation of either continuous nocturnal oxygen use OR moderate-to-severe pulmonary function impairment); significant cardiac disease (e.g., NYHA class III/IV heart failure or history of ventricular fibrillation/sustained ventricular tachycardia in the absence of an implanted defibrillator); neurologic or neuromuscular disease (e.g., stroke with significant residual effects, Parkinson disease, myotonic dystrophy, ALS); hypoventilation syndrome; concern for significant non-respiratory sleep disorder(s) that require evaluation or interfere with HSAT; or signs/symptoms suggestive of OSA as further defined in policy.

List derived from policy I.B items

Repeat Therapy

Covered when ALL of the following are met

Prior PSG: All of the criteria in section I.B are met

Study frequency: The requested study and any previous studies amount to or less per rolling two year period

Policy states a limit for rolling two-year period

Indications for repeat study: At least one of the following: oral appliance adjusted for fit and requires assessment of efficacy; change of device due to intolerance of current device; assessment whether PAP settings need change (including continued symptoms despite adherent use defined as >=4 hours/night for 70% of nights over a 30-day period); significant weight loss (>=10%) in a member using PAP to determine if it can be discontinued; significant weight gain or recurrent symptoms prompting reassessment of PAP; postoperative assessment of efficacy after upper airway surgery; remote history of OSA with need to re-establish diagnosis and/or initiate CPAP; new signs or symptoms in a member with a previous negative study >= 6 months earlier.

Titration

Covered when ONE of the following is met

Titration indications: Facility-based CPAP/BiPAP titration is medically necessary when one of the following is met: (A) the member meets criteria in section I for a facility-based sleep study and has not attempted a home-based study for titration of APAP; or (B) the member was diagnosed with OSA during HSAT and there is documentation of failure of an APAP trial (for example, downloaded compliance data).

Overall medical necessity criteria (summary)

Policy includes initial facility-based PSG criteria and newly added sections for repeat facility-based PSG/split-night studies and facility-based titration.

New and revised criteria overview: Sections II and III were added for repeat facility-based PSG/split-night studies and facility-based titration. Multiple subsections in Section I were revised: hypoventilation syndrome was added as an indication; the pulmonary disease requirement was clarified to require either chronic nocturnal oxygen use OR moderate-to-severe pulmonary function impairment; the Epworth Sleepiness Scale requirement was removed; wording was updated to add diagnosis of hypertension in one subsection and to refine concerns for significant non-respiratory sleep disorders. CPT code 95811 was added to supported facility-based PSG/titration codes.

Full, detailed AND/OR logic for each numbered subsection is contained in other parts of the policy.

Actigraphy testing (CPT 95803) performed alone is not supported as a diagnostic test for obstructive sleep apnea (OSA). The policy identifies actigraphy as a non‑supported diagnostic modality and does not consider isolated actigraphy sufficient to establish an OSA diagnosis.

The policy revisions removed certain prior criteria specific to central sleep apnea: sections III.C and III.D that addressed central apnea were deleted. The update also added and clarified multiple sections, including addition of repeat facility-based PSG/split‑night and facility‑based titration criteria (Sections II and III) and wording changes to I.B subsections, while retaining focus on facility-based evaluation where indicated.

Home sleep apnea testing (HSAT) may be valid for selected high‑probability, uncomplicated patients because it measures fewer physiologic variables and can be convenient, but the policy specifies that actigraphy alone is unsupported/insufficient for diagnosing OSA. Actigraphy records activity but does not capture the full physiologic monitoring provided by polysomnography, and therefore is considered not medically necessary as a stand‑alone diagnostic tool for OSA.

The policy removed prior language describing patients as “moderate‑to‑high‑risk” and eliminated the requirement for the Epworth Sleepiness Scale score. The not‑medically‑necessary framing was updated accordingly, and specific NMN conditions tied to those removed elements were adjusted to reflect the revised criteria and symptom descriptors (for example, adding habitual loud snoring and diagnosis of hypertension into certain subsections).

CPT / Coding Guidance

Covered CPT CodesCPTCovered

95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate,and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older; staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older; staging with 4 or more additional parameters of sleep with initiation of continuous positive airway pressure or bilevel ventilation, attended by a technologist.

Not supported / not coveredCPTNot Covered

95803

Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).

Covered CPT Codes (added)CPTCovered

95811

Facility-based PSG/titration code added to policy

OSA diagnostic thresholds (ICSD definition)

ICSD diagnostic thresholds>= 5 predominantly obstructive respiratory events per hour in the presence of symptoms or certain comorbidities; OR >= 15 predominantly obstructive respiratory events per hour in asymptomatic patients.

Event type specifiedPredominantly obstructive respiratory events (per ICSD definition).

Symptom requirementThreshold of >=5 events/hr applies when patient has symptoms or certain comorbidities.

Asymptomatic thresholdThreshold of >=15 events/hr applies for asymptomatic patients.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required when the policy criteria apply for facility-based polysomnography (PSG), split-night studies, and facility-based titration studies. Facility-based PSG requests (including split-night and titration codes) may be denied if the member meets criteria appropriate for home sleep apnea testing (HSAT) or if facility criteria are not met.

Affected codes include facility PSG and titration CPT codes (e.g., 95810, 95811)
Prior authorization documentation must demonstrate why HSAT is not appropriate when applicable

Documentation Required

Documentation for Repeat Studies

Provide clinical documentation to support repeat facility-based PSG/split-night studies within the rolling two-year window. Documentation should include prior study dates, results, and the clinical rationale for repeating the study (for example: device change due to intolerance, adjusted oral appliance requiring efficacy assessment, significant weight change, new or recurrent symptoms, or postoperative assessment). Failure to document prior studies and rationale may result in denial.

Clinical Background

Obstructive sleep apnea (OSA) is characterized by repeated upper airway collapse during sleep and is diagnosed using physiologic monitoring. Polysomnography (PSG) is the standard diagnostic test because it continuously records multiple physiologic parameters during sleep (respiratory flow and effort, oximetry/ventilation, ECG/heart rate and sleep staging) that are interpreted by a clinician. Home sleep apnea testing (HSAT) is an alternative for selected high‑pretest‑probability, uncomplicated adults but measures fewer variables and may under‑detect events in some populations, so facility‑based PSG is preferred when HSAT is inappropriate or when comorbidities or other concerns exist.

Key Definitions

Definition of Polysomnography (PSG)

DefinitionPolysomnography (PSG) is a comprehensive study that monitors multiple physiologic parameters during sleep including respiratory flow, respiratory effort, oximetry/ventilation, ECG/heart rate, and sleep staging, interpreted by a clinician.

UsesUsed for diagnosis of sleep-disordered breathing, certain parasomnias, narcolepsy, sleep-related movement disorders, and for positive airway pressure titration and assessment of therapy adequacy.

Study formatsConducted as a full-night study or a split-night study (diagnosis in first part, titration in second part if OSA diagnosed).

Definition of Home Sleep Apnea Testing (HSAT)

DefinitionHome Sleep Apnea Testing (HSAT) refers to home-based sleep monitoring using type 3 or type 4 devices that measure fewer physiologic variables than PSG and are interpreted by an expert.